Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Journey MedicalDERM +1.57%63 3-Year EBITDA Growth Rate is 53.10% as of Mar. 2026, which is 7% above its 10-year median of 49.60. GuruFocus rates DERM with a GF Score™ of 63/100 and a GF Value™ of $4.28 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 813 Drug Manufacturers companies, Journey Medical ranks better than 89.91% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 53.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Journey Medical was 53.10% per year. The lowest was -53.20% per year. And the median was 49.60% per year.
Journey Medical (NAS:DERM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Journey Medical 3-Year EBITDA Growth Rate Related Terms
DERM vs LFCR, ADCT, ANIK: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Journey Medical's 3-Year EBITDA Growth Rate falls into.
Journey Medical 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 53.10% mean?
Journey Medical (DERM) has a 3-Year EBITDA Growth Rate of 53.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Journey Medical and its competitors. This is near median its historical median of 49.60. According to the industry distribution chart, Journey Medical ranks #82 out of 813 companies in the Drug Manufacturers industry, placing it in the top 10.1%.
Is Journey Medical's 3-Year EBITDA Growth Rate too high?
Journey Medical's current 3-Year EBITDA Growth Rate of 53.10% is near median its 10-year median of 49.60. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Journey Medical's value of 53.10% is 503.4% above this industry median. Based on the distribution chart, Journey Medical ranks #82 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Journey Medical has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's 3-Year EBITDA Growth Rate compare to LFCR and ADCT?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #82 out of 813 companies for 3-Year EBITDA Growth Rate. This places Journey Medical in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. Journey Medical's value of 53.10% is 503.4% above this benchmark. While the company's 10-year median is 49.60 vs. the industry median of 8.80, Journey Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Journey Medical's current 3-Year EBITDA Growth Rate of 53.10% is 503.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Journey Medical and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Journey Medical's current 3-Year EBITDA Growth Rate is 53.10%, which is near median its own 10-year median of 49.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.28, compared to a current price of $6.49 — trading 51.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 53.10%, which is near median its 10-year median of 49.60 and 503.4% above the Drug Manufacturers industry median of 8.80. Journey Medical's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Journey Medical (DERM), the current 3-Year EBITDA Growth Rate is 53.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $6.49 is trading 51.6% above its estimated GF Value™ of $4.28.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
3-Year EBITDA Growth Rate: 53.10% (near median its 10-year median of 49.60)
GF Value™: $4.28 vs. price of $6.49 (51.6% above fair value)
Industry Position: 503.4% above the Drug Manufacturers median (#82 of 813)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
63GF Score
Get the complete analysis for DERM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
